Alexion Pharmaceuticals Reports Positive Data from Study

Alexion Pharmaceuticals reported early Monday data showing that the benefits of Strensiq (asfotase alfa) achieved in adolescents and adults with hypophosphatasia (HPP) within the first six months were sustained through five years of treatment.

The results were presented at the European Calcified Tissue Society (ECTS) Congress in Austria, and demonstrate a reduction in two key biomarkers of HPP disease activity, as well as improvements in physical function in patients treated with Strensiq.Strensiq was generally well-tolerated, and the most common treatment-related adverse events were mild to moderate injection-site reactions HPP is a genetic, chronic, progressive, and potentially life-threatening ultra-rare metabolic disease.